Phase 2 N=73 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 35 percent of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Trial of IMO-8400 in Adult Patients With Dermatomyositis
Dermatomyositis
Primary: To Assess the Safety and Tolerability of IMO-8400 in Adult Subjects With DM — 6; 4; 2; 4 participants
Phase 2 N=20 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Peripheral T-cell Lymphoma
Primary: Complete Remission (CR) Rate — 3 Participants
Phase 2 N=79 Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
COPD
Primary: Change From Baseline in Peak FEV1 on Day 3 — 0.565; 0.506; 0.519 Liters — p=0.168
Phase 2 N=52 Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne
Acne Vulgaris
Primary: Total Inflammatory Facial Lesion Count at Day 85 — 21.9; 20.3; 18.5 Lesions
Phase 2 N=18 Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
Liver Fibrosis · Hepatitis C · HIV
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events — 100; 100; 100 percentage of participants
Phase 2 N=65 A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Patients With Newly Diagnosed Glioblastoma
Primary: Summary of the Median Progression-free Survival (mPFS) in the Combined 800 mg, 5 Days/Week Dose Group — 6.7; 6.9 months
Phase 2 N=4 High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Neuroblastoma
Primary: Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival
Phase 2 N=110 Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 87.7; 92.5 Probability (%) — p=0.1225
Phase 2 N=37 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Phase 2 N=32 Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 78.1; 72.2; 80.0; 85.7 percentage of participants
Phase 2 N=17 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rate (ORR) — 0 Participants
Phase 2 N=27 Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial
Diabetic Macular Edema
Primary: Macular Thickness at 3 Days After Intravitreous Dexamethasone — 438.44; 465.22; 368.22 µm
Phase 2 N=75 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Prostate Adenocarcinoma · Prostate Cancer · High Risk Prostate Cancer
Primary: Percentage of Participants With Pathologic Complete Response (pCR) or Minimal Residual Disease (MRD) — 30; 16 percentage of participants — p=0.151
Phase 2 N=93 GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
Previously Treated Metastatic Adenocarcinoma of the Pancreas
Primary: Overall Survival (OS) — 5.88; 6.11 months